These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 1426667

  • 1. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L, Csizer Z, Sparkes JD.
    Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
    [Abstract] [Full Text] [Related]

  • 2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF.
    N Engl J Med; 1991 Oct 24; 325(17):1205-9. PubMed ID: 1922207
    [Abstract] [Full Text] [Related]

  • 4. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    Prog Clin Biol Res; 1989 Oct 24; 310():237-52. PubMed ID: 2505269
    [Abstract] [Full Text] [Related]

  • 5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP, van der Meijden PM, Roos EP, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FM.
    Prog Clin Biol Res; 1992 Oct 24; 378():59-67. PubMed ID: 1301587
    [No Abstract] [Full Text] [Related]

  • 6. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S, Hayashi M, Kanatake H.
    Urology; 2004 Jun 24; 63(6):1084-8. PubMed ID: 15183955
    [Abstract] [Full Text] [Related]

  • 7. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL, Crissmann J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J.
    Prog Clin Biol Res; 1989 Jun 24; 310():263-70. PubMed ID: 2672016
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR, Levi d'Ancona CA, Claro JF, Ilari O.
    Arch Esp Urol; 1991 Oct 24; 44(8):1025-8. PubMed ID: 1796850
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989 Oct 24; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Oct 24; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 17. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
    Mori K, Lamm DL, Crawford ED.
    Urol Int; 1986 Oct 24; 41(4):254-9. PubMed ID: 3538593
    [Abstract] [Full Text] [Related]

  • 18. Long-term results of intravesical therapy for superficial bladder cancer.
    Lamm DL.
    Urol Clin North Am; 1992 Aug 24; 19(3):573-80. PubMed ID: 1636241
    [Abstract] [Full Text] [Related]

  • 19. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul 24; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 20. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA, Lamm DL, van der Meijden AP, Debruyne FM.
    Prog Clin Biol Res; 1989 Jul 24; 310():311-23. PubMed ID: 2672019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.